{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:10:20Z","timestamp":1761059420507,"version":"build-2065373602"},"reference-count":126,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":2290,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.bbmt.2008.10.010","type":"journal-article","created":{"date-parts":[[2009,1,14]],"date-time":"2009-01-14T04:25:10Z","timestamp":1231907110000},"page":"114-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S","title":["Oncogenic Signals as Treatment Targets in Classic Myeloproliferative Neoplasms"],"prefix":"10.1016","volume":"15","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross L.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2008.10.010_bib1","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bbmt.2008.10.010_bib2","first-page":"1497","article-title":"A minute chromosome in human granulocytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2008.10.010_bib3","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.1073\/pnas.87.17.6649","article-title":"Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR\/ABL","volume":"87","author":"Kelliher","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2008.10.010_bib4","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2008.10.010_bib5","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/j.1460-2075.1990.tb08212.x","article-title":"bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice","volume":"9","author":"Elefanty","year":"1990","journal-title":"EMBO J"},{"key":"10.1016\/j.bbmt.2008.10.010_bib6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbmt.2008.10.010_bib7","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2008.10.010_bib8","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2008.10.010_bib9","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2008.10.010_bib10","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.bbmt.2008.10.010_bib11","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2008.10.010_bib12","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib13","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","article-title":"Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2008.10.010_bib14","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders","volume":"111","author":"Pietra","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib15","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1073\/pnas.58.4.1468","article-title":"Clonal origin of chronic myelocytic leukemia in man","volume":"58","author":"Fialkow","year":"1967","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2008.10.010_bib16","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2008.10.010_bib17","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/299747a0","article-title":"Chromosomal localization of human cellular homologues of two viral oncogenes","volume":"299","author":"Heisterkamp","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2008.10.010_bib18","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/300765a0","article-title":"A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia","volume":"300","author":"de Klein","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2008.10.010_bib19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22","volume":"36","author":"Groffen","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.bbmt.2008.10.010_bib20","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/315758a0","article-title":"Structural organization of the bcr gene and its role in the Ph\u2032 translocation","volume":"315","author":"Heisterkamp","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2008.10.010_bib21","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(84)90997-8","article-title":"Altered transcription of an oncogene in chronic myeloid leukaemia","volume":"1","author":"Canaani","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2008.10.010_bib22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1126\/science.6587568","article-title":"Altered transcription of the c-abl oncogene in K-562 and other chronic myelogenous leukemia cells","volume":"225","author":"Collins","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2008.10.010_bib23","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/315550a0","article-title":"Fused transcript of abl and bcr genes in chronic myelogenous leukaemia","volume":"315","author":"Shtivelman","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2008.10.010_bib24","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198512053132301","article-title":"Evidence of a new chimeric bcr\/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome","volume":"313","author":"Stam","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2008.10.010_bib25","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.3460176","article-title":"The chronic myelogenous leukemia-specific P210 protein is the product of the bcr\/abl hybrid gene","volume":"233","author":"Ben-Neriah","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2008.10.010_bib26","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.bbmt.2008.10.010_bib27","first-page":"100","article-title":"Inhibition of the\u00a0Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2008.10.010_bib28","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1073\/pnas.92.7.2558","article-title":"Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2- phenylaminopyrimidine class","volume":"92","author":"Buchdunger","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2008.10.010_bib29","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1182\/blood.V97.8.2440","article-title":"ARG tyrosine kinase activity is inhibited by STI571","volume":"97","author":"Okuda","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib30","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib31","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2008.10.010_bib32","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2008.10.010_bib33","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2008.10.010_bib34","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2008.10.010_bib35","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib36","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib37","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood.V99.10.3547","article-title":"Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase","volume":"99","author":"Kantarjian","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib38","first-page":"2167","article-title":"Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate","volume":"8","author":"Kantarjian","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2008.10.010_bib39","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","article-title":"A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias","volume":"100","author":"Ottmann","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib40","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S0140-6736(01)06535-7","article-title":"Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study","volume":"358","author":"van Oosterom","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2008.10.010_bib41","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2008.10.010_bib42","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)08505-7","article-title":"Treatment of hypereosinophilic syndrome with imatinib mesilate","volume":"359","author":"Gleich","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2008.10.010_bib43","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2008.10.010_bib44","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2008.10.010_bib45","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2002-10-3103","article-title":"Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders","volume":"101","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib46","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","article-title":"Imatinib for systemic mast-cell disease","volume":"362","author":"Pardanani","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2008.10.010_bib47","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in\u00a0systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib48","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","article-title":"FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib49","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib50","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2008.10.010_bib51","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2008.10.010_bib52","doi-asserted-by":"crossref","first-page":"9244","DOI":"10.1073\/pnas.0600001103","article-title":"Activity of dual SRC-ABL inhibitors highlights the role of BCR\/ABL kinase dynamics in drug resistance","volume":"103","author":"Azam","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2008.10.010_bib53","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2008.10.010_bib54","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2008.10.010_bib55","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1056\/NEJMe068073","article-title":"Circumventing resistance to kinase-inhibitor therapy","volume":"354","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2008.10.010_bib56","doi-asserted-by":"crossref","first-page":"11011","DOI":"10.1073\/pnas.0504952102","article-title":"Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases","volume":"102","author":"Carter","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2008.10.010_bib57","doi-asserted-by":"crossref","first-page":"20059","DOI":"10.1074\/jbc.R700016200","article-title":"JAK-STAT signaling: from interferons to cytokines","volume":"282","author":"Schindler","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bbmt.2008.10.010_bib58","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1182\/blood.V90.7.2535","article-title":"Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia","volume":"90","author":"Peeters","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib59","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.278.5341.1309","article-title":"A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia","volume":"278","author":"Lacronique","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2008.10.010_bib60","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1158\/0008-5472.CAN-04-4263","article-title":"The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2","volume":"65","author":"Reiter","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2008.10.010_bib61","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/sj.leu.2403879","article-title":"PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation","volume":"19","author":"Murati","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2008.10.010_bib62","doi-asserted-by":"crossref","first-page":"7248","DOI":"10.1038\/sj.onc.1208850","article-title":"The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene","volume":"24","author":"Bousquet","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.bbmt.2008.10.010_bib63","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.leu.2404104","article-title":"A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma","volume":"20","author":"Adelaide","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2008.10.010_bib64","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/gcc.20235","article-title":"A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia","volume":"44","author":"Griesinger","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.bbmt.2008.10.010_bib65","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and myelodysplastic syndromes","volume":"106","author":"Steensma","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib66","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib67","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.leu.2404036","article-title":"Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma","volume":"20","author":"Melzner","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2008.10.010_bib68","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/10428190500271723","article-title":"JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas","volume":"47","author":"Lee","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2008.10.010_bib69","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1365-2141.2005.05697.x","article-title":"The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia","volume":"130","author":"Sulong","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2008.10.010_bib70","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2005-05-1898","article-title":"The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia","volume":"106","author":"Levine","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib71","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1080\/02841860500341223","article-title":"Absence of JAK2 V617F mutation in gastric cancers","volume":"45","author":"Lee","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.bbmt.2008.10.010_bib72","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/sj.onc.1209163","article-title":"The JAK2 V617F mutation in de novo acute myelogenous leukemias","volume":"25","author":"Lee","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.bbmt.2008.10.010_bib73","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2005-05-2087","article-title":"The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders","volume":"106","author":"Scott","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib74","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2141.2005.05743.x","article-title":"Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia","volume":"131","author":"Tefferi","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2008.10.010_bib75","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1182\/blood-2005-05-1889","article-title":"Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2","volume":"106","author":"Kralovics","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib76","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/sj.leu.2404206","article-title":"JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained","volume":"20","author":"Steensma","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2008.10.010_bib77","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1038\/sj.leu.2404405","article-title":"High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"20","author":"Renneville","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2008.10.010_bib78","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1038\/sj.leu.2404379","article-title":"JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?","volume":"20","author":"Verstovsek","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2008.10.010_bib79","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/sj.leu.2404086","article-title":"JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients","volume":"20","author":"Vizmanos","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2008.10.010_bib80","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","article-title":"Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model","volume":"107","author":"Wernig","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib81","doi-asserted-by":"crossref","unstructured":"Lacout C, Pisani DF, Tulliez M, Moreau Gachelin F, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. (First Edition Paper, prepublished online May 2, 2006; DOI:101182\/blood-2006-02-002030.)","DOI":"10.1182\/blood-2006-02-002030"},{"key":"10.1016\/j.bbmt.2008.10.010_bib82","doi-asserted-by":"crossref","unstructured":"Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild type JAK2 determines the MPD phenotypes in\u00a0transgenic mice. Blood. (First Edition Paper, prepublished online December 26, 2007; DOI:101182\/blood-2007-08-107748.)","DOI":"10.1182\/blood.V110.11.674.674"},{"key":"10.1016\/j.bbmt.2008.10.010_bib83","doi-asserted-by":"crossref","unstructured":"Shide K, Shimoda HK, Kumano T, et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia. (advance online publication 22 November 2007; doi:101038\/sjleu2405043.)","DOI":"10.1038\/sj.leu.2405043"},{"key":"10.1016\/j.bbmt.2008.10.010_bib84","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.22663","article-title":"Clinical correlates of JAK2V617F allele burden in essential thrombocythemia","volume":"109","author":"Kittur","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2008.10.010_bib85","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/sj.leu.2404724","article-title":"Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera","volume":"21","author":"Tefferi","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2008.10.010_bib86","first-page":"676","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, predicts inferior overall and leukemia-free survival","volume":"110","author":"Tefferi","year":"2007","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.bbmt.2008.10.010_bib87","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib88","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2006-10-054940","article-title":"The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera","volume":"110","author":"Dupont","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib89","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain of function mutation in Jak2 is frequently found in patients with myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2008.10.010_bib90","doi-asserted-by":"crossref","unstructured":"Lippert E, Boissinot M, Kralovics R, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood. (First Edition Paper, prepublished online May 25, 2006; DOI:101182\/blood-2006-01-013540.)","DOI":"10.1182\/blood-2006-01-013540"},{"key":"10.1016\/j.bbmt.2008.10.010_bib91","unstructured":"Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F JAK2 mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood. (First Edition aper, prepublished online June 13, 2006: DOI:101182\/blood-2006-04-018259.)"},{"key":"10.1016\/j.bbmt.2008.10.010_bib92","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1073\/pnas.0601462103","article-title":"The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation","volume":"103","author":"Jamieson","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2008.10.010_bib93","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMc051878","article-title":"JAK2 mutations in myeloproliferative disorders","volume":"353","author":"Tefferi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2008.10.010_bib94","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2006-03-007146","article-title":"Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis","volume":"109","author":"Delhommeau","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib95","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2141.2005.05682.x","article-title":"Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes","volume":"130","author":"Lasho","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2008.10.010_bib96","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood-2005-12-4852","article-title":"Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders","volume":"108","author":"Bellanne-Chantelot","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib97","doi-asserted-by":"crossref","unstructured":"Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic cell lineages by the JAK2V617F mutation in polycythemia vera. Blood. (First Edition Paper, prepublished online June 6, 2006; DOI:101182\/blood-2006-04-017392.)","DOI":"10.1182\/blood-2006-04-017392"},{"key":"10.1016\/j.bbmt.2008.10.010_bib98","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1634\/stemcells.2007-0175","article-title":"Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes","volume":"25","author":"Pardanani","year":"2007","journal-title":"Stem Cells"},{"key":"10.1016\/j.bbmt.2008.10.010_bib99","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2005-11-009605","article-title":"Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders","volume":"108","author":"Kralovics","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib100","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.exphem.2006.11.012","article-title":"Polycythemia vera is not initiated by JAK2(V617F) mutation","volume":"35","author":"Nussenzveig","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2008.10.010_bib101","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","article-title":"Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation","volume":"110","author":"Theocharides","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib102","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","article-title":"Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation","volume":"108","author":"Campbell","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib103","unstructured":"Pardanani A, Fridley BL, Lasho TL, Gilliland DG, Tefferi A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood. (R 101182\/blood-2007-06-095703.)"},{"key":"10.1016\/j.bbmt.2008.10.010_bib104","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"Somatic mutations of JAK2 exon 12 in polycythemia vera and idiopathic erythrocytosis","volume":"365","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2008.10.010_bib105","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2141.2007.06806.x","article-title":"Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera","volume":"139","author":"Scott","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2008.10.010_bib106","doi-asserted-by":"crossref","unstructured":"Butcher CM, Hahn U, To LB, et al. Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients. Leukemia. (advance online publication 4 October 2007; Doi:101038\/sjleu2404971.)","DOI":"10.1038\/sj.leu.2404971"},{"key":"10.1016\/j.bbmt.2008.10.010_bib107","doi-asserted-by":"crossref","unstructured":"Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon\u00a012 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. (First Edition Paper, prepublished online November 6, 2007; DOI:101182\/blood-2007-07-101576.)","DOI":"10.1182\/blood.V110.11.263.263"},{"key":"10.1016\/j.bbmt.2008.10.010_bib108","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3324\/haematol.11643","article-title":"The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels","volume":"92","author":"Percy","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2008.10.010_bib109","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3324\/haematol.12011","article-title":"JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis","volume":"92","author":"Martinez-Aviles","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2008.10.010_bib110","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib111","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/369565a0","article-title":"Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo","volume":"369","author":"Lok","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2008.10.010_bib112","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1056\/NEJMra052706","article-title":"Lineage-specific hematopoietic growth factors","volume":"354","author":"Kaushansky","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2008.10.010_bib113","doi-asserted-by":"crossref","first-page":"5186","DOI":"10.1182\/blood-2006-08-044503","article-title":"Studies of c-Mpl function distinguish the replication of hematopoietic stem cells from the expansion of differentiating clones","volume":"109","author":"Abkowitz","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib114","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood-2003-10-3471","article-title":"Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin","volume":"103","author":"Ding","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib115","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1073\/pnas.96.6.3132","article-title":"Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia","volume":"96","author":"Ihara","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2008.10.010_bib116","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood.V97.1.139","article-title":"c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia","volume":"97","author":"Ballmaier","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib117","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/humu.9415","article-title":"MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease","volume":"27","author":"Germeshausen","year":"2006","journal-title":"Hum Mutat"},{"key":"10.1016\/j.bbmt.2008.10.010_bib118","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib119","first-page":"2546","article-title":"Detection of three different MPLW515 mutations in 10.1% of all JAK2 V617 unmutated ET and 9.3% of all JAK2 V617F unmutated OMF: a study of 387 patients","volume":"110","author":"Schnittger","year":"2007","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.bbmt.2008.10.010_bib120","first-page":"677","article-title":"Clinical significance of MPL mutations in essential thrombocythemia: analysis of the PT-1 cohort","volume":"110","author":"Beer","year":"2007","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.bbmt.2008.10.010_bib121","first-page":"678","article-title":"The clinical phenotype of patients with essential thrombocythemia harboring MPL 515W>L\/m mutation","volume":"110","author":"Vannucchi","year":"2007","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.bbmt.2008.10.010_bib122","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2007.06565.x","article-title":"Anaemia characterises patients with myelofibrosis harbouring Mpl mutation","volume":"137","author":"Guglielmelli","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2008.10.010_bib123","article-title":"Extending JAK2V617F and MPL515 mutation analysis to single myeloid colonies and T and B lymphocytes","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib124","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2007-05-089003","article-title":"Evidence for MPL W515L\/K mutations in hematopoietic stem cells in primitive myelofibrosis","volume":"110","author":"Chaligne","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.10.010_bib125","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/sj.leu.2404749","article-title":"Demonstration of MPLW515K, but not JAK2V617F, in in vitro expanded CD4+ T lymphocytes","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2008.10.010_bib126","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1365-2141.2006.06348.x","article-title":"Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time","volume":"135","author":"Lasho","year":"2006","journal-title":"Br J Haematol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879108004461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879108004461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:33:41Z","timestamp":1761057221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879108004461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":126,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S1083879108004461"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2008.10.010","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2009,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncogenic Signals as Treatment Targets in Classic Myeloproliferative Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2008.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}